Document is current
Any future updates will be listed below
-
Authors
Kim, Dong Hyun
Kang, Mingu
Park, Gahee
Mostafavi, Mohammad
Lim, Yoojoo
Ock, Chan-Young
Koh, Jiwon
Jeon, Yoon Kyung
Jung, Kyeong Cheon
Ahn, Soon-Hyun
Chung, Eun-Jae
Kwon, Seong-Keun
Keam, Bhumsuk
- License Information
-
More Information
Article History
Received: 15 March 2024
Accepted: 1 November 2024
First Online: 20 November 2024
Declarations
:
: This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol was approved by the Institutional Review Board of the Seoul National University Hospital (approval no. H-2306-142-1440).The requirement for informed consent was waived by the Institutional Review Board because of the study’s retrospective nature.
: B.K. received research funding from MSD, AstraZeneca, and Ono Pharmaceutical Co., Ltd., and has served as an advisor for Handok, NeoImmuneTec, Trialinformatics and ImmuneOncia outside of the current work. M.K., G.P., and Y.L. are employees of Lunit, and CY.O. holds a leadership position and is a stock owner of Lunit.
